---
title: "Jiangsu Hengrui Pharmaceuticals Gets China Nod for Two Anti-Tumor Injectables"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/278349440.md"
description: "Jiangsu Hengrui Pharmaceuticals Gets China Nod for Two Anti-Tumor Injectables"
datetime: "2026-03-09T07:46:07.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/278349440.md)
  - [en](https://longbridge.com/en/news/278349440.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/278349440.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/278349440.md) | [繁體中文](https://longbridge.com/zh-HK/news/278349440.md)


# Jiangsu Hengrui Pharmaceuticals Gets China Nod for Two Anti-Tumor Injectables



### 相关股票

- [Hengrui Pharma (600276.CN)](https://longbridge.com/zh-CN/quote/600276.CN.md)
- [Bosera Hang Seng SCHK Innovative Drug Select ETF (520690.CN)](https://longbridge.com/zh-CN/quote/520690.CN.md)
- [Bosera Hang Seng Health Care ETF(QDII) (513060.CN)](https://longbridge.com/zh-CN/quote/513060.CN.md)
- [Ping An CSI Medicine and Medical Device Innovation ETF (516820.CN)](https://longbridge.com/zh-CN/quote/516820.CN.md)
- [Ping An SSE 180 ETF (530280.CN)](https://longbridge.com/zh-CN/quote/530280.CN.md)

## 相关资讯与研究

- [Hengrui Pharmaceuticals Obtains Nod for Lung Cancer Combo Drug Trials](https://longbridge.com/zh-CN/news/277871128.md)
- [Hengrui Pharmaceuticals Gets Clinical Trial Nod for Hypertension Drug](https://longbridge.com/zh-CN/news/277870666.md)
- [Hengrui Pharmaceuticals Gets Nod to Trial SHR-9803 for Injection](https://longbridge.com/zh-CN/news/278830096.md)
- [Kainova reports positive top line results from Phase I EPRAD trial](https://longbridge.com/zh-CN/news/278702903.md)
- [Hengrui Pharma Gets Nod for Solid Tumor Injection's Clinical Trials](https://longbridge.com/zh-CN/news/273791098.md)